Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome

Published:2023-03 Issue:3 Volume:23 Page:e164-e170
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Beksac Meral^ORCID,Seval Guldane Cengiz,Koyun Derya^ORCID,Topcuoglu Pervin,Yuksel Meltem-Kurt,Gurman Gunhan,Ilhan Osman^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference21 articles.

1. CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma;Morandi;Front Immunol,2018

2. Improved survival in multiple myeloma and the impact of novel therapies;Kumar;Blood,2008

3. A comparison of the efficacy of immunomodulatory-containing regimens in relapsed/refractory multiple myeloma: a network meta-analysis;Dimopoulos;Clin Lymphoma Myeloma Leuk,2018

4. Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience;Holstein;Drugs,2017

5. Safety and efficacy of lenalidomide in relapsed or refractory multiple myeloma;Alegre;Clin Med Insights Oncol,2012

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metal-free synthesis strategies towards amide bond formation: review;Processes of Petrochemistry and Oil Refining;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP